source
- UniQure slated for FDA decision by May 1 as analysts see potential for first Huntington’s disease therapyUniQure said the Food and Drug Administration has set a decision date for its Huntington's disease gene therapy and is likely to hold an advisory committee meeting. The agency indicated a faster‑th…
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugOn a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.